Although HER2 is not yet definitively established as an independent prognostic factor for bladder cancer, its expression often accompanies more aggressive phenotypes and may delineate subgroups at higher risk (for example, BCG-refractory superficial carcinomas or micropapillary invasive forms). Here, ERBB2 is linked to urinary bladder cancer.